Single Dose Versus Double Dose Tamsulosin in Management of Moderate and Severe LUTS Due to BPH

Prostatic Neoplasms Clinical Trial

Official title:

Single Dose Versus Double Dose Tamsulosin in Management of Moderate and Severe Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05834270
• Other study ID #: SD vs DD Tamsulosin
• Status: Completed
• Phase: N/A
• Start date: May 1, 2022
• Est. completion date: December 1, 2022

Study information

• Verified date: April 2023
• Source: Menoufia University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Single dose versus double dose tamsulosin in Management of Moderate and severe lower urinary tract symptoms due to benign prostatic hyperplasia

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: December 1, 2022
• Est. primary completion date: December 1, 2022
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 50 Years to 80 Years

Eligibility

Inclusion Criteria:

• age more than 50 years

• moderate to severe lower urinary tract symptoms

Exclusion Criteria:

• prostatic cancer

• urethral stricture

• prostate surgery

• Neurogenic bladder

Related Conditions & MeSH terms

• Hypertrophy
• Prostate Disease
• Prostate Hypertrophy
• Prostate Obstruction
• Prostatic Diseases
• Prostatic Hyperplasia
• Prostatic Neoplasms

Intervention

Drug:
• Single dose tamsulosin 0.4mg
Single dose tamsulosin 0.4mg
• Double dose tamsulosin 0.4mg
Double dose tamsulosin 0.4mg

Locations

Country	Name	City	State
Egypt	Faculty of Medicine	Shibin Al Kawm	Menofia

Sponsors (1)

Lead Sponsor	Collaborator
Menoufia University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in the lower urinary tract symptoms	Assessed by the improvement in the internal prostatic symptoms score (IPSS)	3 months